X
Xenon Pharmaceuticals
From families to genes, from genes to drugs.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address neurological disorders. The company operates primarily in the healthcare and pharmaceutical markets, targeting conditions such as epilepsy and other central nervous system disorders. Xenon's business model revolves around the research, development, and commercialization of novel therapies. Revenue is generated through partnerships, licensing agreements, and potential future product sales. The company serves a diverse client base, including healthcare providers, patients, and research institutions. Xenon leverages its expertise in genetics and neurology to create a robust pipeline of drug candidates, currently highlighted by its Phase 2 proof of concept study for XEN007 in pediatric patients with treatment-resistant childhood absence epilepsy (CAE). The company's strategic focus on unmet medical needs and its commitment to advancing neurology therapies position it as a key player in the biopharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2014
Open roles
Xenon Pharmaceuticals in the Burnaby ecosystem
The Xenon Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
InterWest Partners
GrowthWorks Capital
Novo Ventures
RBC Venture Partners
JP Morgan
Invesco Private Capital
Takeda
Series B and later2 investors entered at this stage
Northview LifeSciences
Neurocrine Biosciences
Source: Dealroom Talent Intelligence.
Patents
68 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Xenon Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Xenon pauses Phase 3 depression trials of azetukalner after side-effect reports
